|
|
|
Blood and Marrow Transplantation Reviews: Volume 14, Issue 2 |
Autoimmune Diseases: When Homeland Security Fails
by John R. Wingard, Editor
Autoimmune disease can be viewed as an insurrection by security forces charged with protecting us from lurking outside dangers. What ensues is either smoldering conflict to attrition or large-scale open warfare. Treatments have generally been disappointing. Autoimmune phenomena are sometimes consequences of both autologous and allogeneic hematopoietic cell transplantation (HCT). So, why would one consider treating autoimmune diseases with HCT?
Serendipity can fuel great initiatives. The incidental findings of concomitant autoimmune diseases improving in patients undergoing HCT for other reasons have been well documented in the literature. Animal models have amply demonstrated the potential of transplantation to correct autoimmune diseases. So, certainly there were reasons to believe that HCT is worthy for study. Now, clinical investigators have compiled an impressive array of early clinical data suggesting the potential for HCT to have an important role in the treatment of human autoimmune diseases.
In this transcript of a symposium held at the 2004 Tandem BMT Meetings in Orlando, Florida, the current status of what we know and what is being learned in clinical trials now underway and those in the planning stages is reviewed.
Much has been learned. Rheumatologists and neurologists have set the stage by defining natural history and risk factors and developing standardized criteria for disease status and response. Transplanters have added knowledge about principles of conditioning regimens, identified treatment risk factors, and defined some of the limits of who might be helped and who cannot.
Yet much work lies ahead. And, of course, obstacles. There are other competing alternative therapies to test, many with less risky complications. What about high-dose immunosuppressive therapy without stem cells? Adjunctive studies to investigate in detail how HCT affects the dysregulated immunity are needed, to increase our understanding of pathogenesis and provide suggestions for yet further interventions. The randomized trials are ambitious and need wide support for timely completion. Only then will we know if an armed counterinsurgency will win the day.
In this issue:
Introduction
Autoimmune Diseases: When Homeland Security Fails
John R. Wingard, MD
Membership Application
ASBMT News
CME Symposium Report: Stem Cell Therapy for Autoimmune Disease
New Indications in Stem Cell Sources in Transplantation for Autoimmune Disease
Richard K. Burt, MD
The European Randomized HSCT Trial for Scleroderma
Dominique Farge, MD, JM van Laar, Alan Tyndall
The European Randomized HSCT Trial for Multiple Sclerosis
Athanasios Fassas, MD
Is There Any Evidence of a Graft-versus-Autoimmunity Effect in Allogeneic Transplantation?
Alberto Marmont, MD
American Randomized Trial for Systemic Lupus Erythematosis
Ann Traynor, MD
Journal Watch
CME Assessment Test
CME Answer Sheet
CME Evaluation Form
 Download a PDF version of the full issue
|
|
|
RSS / Subscribe